WallStreetZenWallStreetZen

NASDAQ: ORKA
Oruka Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ORKA

Based on 3 analysts offering 12 month price targets for Oruka Therapeutics Inc

Min Forecast
$40.00+170.09%
Avg Forecast
$43.33+192.59%
Max Forecast
$45.00+203.85%

Should I buy or sell ORKA stock?

Based on 3 analysts offering ratings for Oruka Therapeutics Inc.

Buy
Strong Buy
0 analysts 0%
Buy
3 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ORKA's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates ORKA as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their ORKA stock forecasts and price targets.

ORKA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-08-18
lockedlocked$00.00+00.00%2025-07-23
lockedlocked$00.00+00.00%2025-05-15

1 of 1

Forecast return on equity

Is ORKA forecast to generate an efficient return?

Company
-27.14%
Industry
122.74%
Market
-47.8%
ORKA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ORKA forecast to generate an efficient return on assets?

Company
-26.09%
Industry
46.26%
ORKA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ORKA earnings per share forecast

What is ORKA's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$2.10
Avg 2 year Forecast
-$2.49
Avg 3 year Forecast
-$2.03

ORKA revenue forecast

What is ORKA's revenue in the next 1 years based on estimates from 1 analyst?

Avg 1 year Forecast
$63.0M

ORKA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ORKA$14.81$43.33+192.59%Buy
ARVN$7.54$15.19+101.51%Buy
ANAB$19.96$54.60+173.55%Buy
XNCR$7.90$21.20+168.35%Buy
SEPN$12.70$23.00+81.10%Buy
View Top Biotech Stocks

Oruka Therapeutics Stock Forecast FAQ

Is Oruka Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: ORKA) stock is to Buy ORKA stock.

Out of 3 analysts, 0 (0%) are recommending ORKA as a Strong Buy, 3 (100%) are recommending ORKA as a Buy, 0 (0%) are recommending ORKA as a Hold, 0 (0%) are recommending ORKA as a Sell, and 0 (0%) are recommending ORKA as a Strong Sell.

If you're new to stock investing, here's how to buy Oruka Therapeutics stock.

What is ORKA's earnings growth forecast for 2025-2027?

(NASDAQ: ORKA) Oruka Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.32%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.39%.

Oruka Therapeutics's earnings in 2025 is -$99,977,000.On average, 6 Wall Street analysts forecast ORKA's earnings for 2025 to be -$78,522,977, with the lowest ORKA earnings forecast at -$95,499,400, and the highest ORKA earnings forecast at -$68,160,356. On average, 6 Wall Street analysts forecast ORKA's earnings for 2026 to be -$93,128,768, with the lowest ORKA earnings forecast at -$117,969,847, and the highest ORKA earnings forecast at -$72,654,445.

In 2027, ORKA is forecast to generate -$76,025,012 in earnings, with the lowest earnings forecast at -$86,136,714 and the highest earnings forecast at -$65,913,311.

What is ORKA's revenue growth forecast for 2031-2031?

(NASDAQ: ORKA) Oruka Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.98%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.98%.

Oruka Therapeutics's revenue in 2025 is $0.

In 2031, ORKA is forecast to generate $2,359,396,935 in revenue, with the lowest revenue forecast at $2,359,396,935 and the highest revenue forecast at $2,359,396,935.

What is ORKA's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: ORKA) forecast ROA is -26.09%, which is lower than the forecast US Biotechnology industry average of 46.26%.

What is ORKA's Price Target?

According to 3 Wall Street analysts that have issued a 1 year ORKA price target, the average ORKA price target is $43.33, with the highest ORKA stock price forecast at $45.00 and the lowest ORKA stock price forecast at $40.00.

On average, Wall Street analysts predict that Oruka Therapeutics's share price could reach $43.33 by Aug 18, 2026. The average Oruka Therapeutics stock price prediction forecasts a potential upside of 192.59% from the current ORKA share price of $14.81.

What is ORKA's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: ORKA) Oruka Therapeutics's current Earnings Per Share (EPS) is -$0.11. On average, analysts forecast that ORKA's EPS will be -$2.10 for 2025, with the lowest EPS forecast at -$2.55, and the highest EPS forecast at -$1.82. On average, analysts forecast that ORKA's EPS will be -$2.49 for 2026, with the lowest EPS forecast at -$3.15, and the highest EPS forecast at -$1.94. In 2027, ORKA's EPS is forecast to hit -$2.03 (min: -$2.30, max: -$1.76).

What is ORKA's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: ORKA) forecast ROE is -27.14%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.